LOGO
LOGO

FDA Calendar - Telix Pharmaceuticals Limited

Company Name Telix Pharmaceuticals Limited
TLX, TLX.AX
Drug Name TLX101-Px1 (resubmitted NDA)
Event Name FDA decision on TLX101-Px1, an agent for the imaging of glioma
Event Date 09/11/2026
Outcome Date
Outcome pending
Drug Status FDA issued complete response letter for TLX101-Px, proposed as an agent for the imaging of glioma, in April 2025.
Rival Drugs
Market Potential
Other Approvals
News